HUMC 1612: Optune NovoTTF-200A System

• Status: Recruiting
• Trial end date: 2019-02-01

Summary

The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in pediatric patients with high-grade glioma, both alone and in combination with standard chemotherapy medications.

• Phase: Phase 1

Details

• Lead Sponsor: Hackensack Meridian Health
• Collaborator: NovoCure Ltd.
• Treatments: Alkylating Agents; Bevacizumab; Dacarbazine; Temozolomide